Marshall Wace LLP Invests $6.42 Million in Catalyst Biosciences Inc (CBIO) Stock

Share on StockTwits

Marshall Wace LLP bought a new stake in Catalyst Biosciences Inc (NASDAQ:CBIO) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 550,352 shares of the biopharmaceutical company’s stock, valued at approximately $6,423,000. Marshall Wace LLP owned approximately 4.61% of Catalyst Biosciences as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of CBIO. Quantitative Systematic Strategies LLC acquired a new stake in shares of Catalyst Biosciences in the 2nd quarter valued at about $120,000. Rhumbline Advisers acquired a new stake in shares of Catalyst Biosciences in the 2nd quarter valued at about $136,000. DRW Securities LLC acquired a new stake in shares of Catalyst Biosciences in the 2nd quarter valued at about $152,000. Alps Advisors Inc. acquired a new stake in shares of Catalyst Biosciences in the 2nd quarter valued at about $201,000. Finally, Wells Fargo & Company MN raised its stake in shares of Catalyst Biosciences by 148.3% in the 1st quarter. Wells Fargo & Company MN now owns 8,940 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 5,340 shares in the last quarter. Institutional investors and hedge funds own 69.17% of the company’s stock.

CBIO has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Wednesday, July 25th. Chardan Capital restated a “buy” rating and issued a $35.00 target price on shares of Catalyst Biosciences in a research note on Tuesday, June 19th. ValuEngine upgraded shares of Catalyst Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. BidaskClub upgraded shares of Catalyst Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, June 19th. Finally, B. Riley lowered shares of Catalyst Biosciences from a “buy” rating to a “neutral” rating and cut their target price for the company from $44.00 to $12.50 in a research note on Thursday, June 21st. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $19.50.

Shares of Catalyst Biosciences stock opened at $9.39 on Friday. Catalyst Biosciences Inc has a 1 year low of $3.80 and a 1 year high of $37.00.

Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.08. Catalyst Biosciences had a negative net margin of 2,983.40% and a negative return on equity of 27.51%. equities research analysts forecast that Catalyst Biosciences Inc will post -2.47 EPS for the current year.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Recommended Story: Risk Tolerance and Your Investment Decisions

Want to see what other hedge funds are holding CBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Biosciences Inc (NASDAQ:CBIO).

Institutional Ownership by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply